Ocata Therapeutics Inc fka OCAT

[rocky301]

2011 Milestones
1Q
•
Designation for hESC-derived RPE Cells for Stargardt’s Disease

2Q
•
Sign clinical trial agreements for SMD and Dry AMD sites
•
Commence patient selection
•
Treat first patients for SMD and Dry AMD Phase I/II clinical trials
•
Secure European EMA “Orphan” approval for SMD program
•
File with European Medicines Agency (EMA) for RPE program

2ndHalf of 2011
•
Treat additional cohorts of patients in RPE Phase I/II trials
•
Early look at data from first cohort of patients in RPE Phase I/II trials
•
Secure approval from EMA for RPE Program
•
Continue partnering and licensing discussions
•
Advance toward IND filing for hemangioblast program